Next year will also bring critical results. One study could lead to the first-ever treatment for a growing liver disease epidemic. The results of a $2 billion Alzheimer’s program could shock skeptics and deliver a desperately-needed treatment, or it could be a crushing blow to a key theory behind Alzheimer’s disease, which is already in deep dispute. In gene therapy, multiple studies could start moving the cutting-edge technology into broader patient populations and force a reckoning over sky-high drug prices.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,